JP Morgan Chase’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $162K | Sell |
9,020
-31,984
| -78% | -$624K | ﹤0.01% | 5732 |
|
|
2026
Q1 | $681K | Buy |
41,004
+17,665
| +76% | +$203K | ﹤0.01% | 4815 |
|
|
2025
Q4 | $277K | Buy |
23,339
+23,322
| +137,188% | +$297K | ﹤0.01% | 5358 |
|
|
2025
Q3 | $202 | Buy |
+17
| New | +$226 | ﹤0.01% | 7110 |
|
|
2025
Q2 | – | Sell |
-1
| Closed | -$26 | – | 7300 |
|
|
2025
Q1 | $26 | Hold |
1
| – | – | ﹤0.01% | 7083 |
|
|
2024
Q4 | $34 | Hold |
1
| – | – | ﹤0.01% | 7194 |
|
|
2024
Q3 | $24 | Sell |
1
-1
| -50% | -$21 | ﹤0.01% | 7231 |
|
|
2024
Q2 | $43 | Sell |
2
-844
| -100% | -$87.7K | ﹤0.01% | 7049 |
|
|
2024
Q1 | $254K | Buy |
846
+830
| +5,188% | +$248K | ﹤0.01% | 5220 |
|
|
2023
Q4 | $3.81K | Buy |
16
+11
| +220% | +$1.71K | ﹤0.01% | 6605 |
|
|
2023
Q3 | $699 | Sell |
5
-3
| -38% | -$473 | ﹤0.01% | 6686 |
|
|
2023
Q2 | $1.37K | Sell |
8
-54
| -87% | -$9.05K | ﹤0.01% | 6409 |
|
|
2023
Q1 | $8K | Buy |
+62
| New | +$14K | ﹤0.01% | 6164 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 6718 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 6600 |
|
|
2022
Q2 | – | Sell |
-15
| Closed | -$1.11K | – | 6626 |
|
|
2022
Q1 | $2K | Buy |
15
+3
| +25% | +$352 | ﹤0.01% | 6419 |
|
|
2021
Q4 | $2K | Sell |
12
-294
| -96% | -$53.4K | ﹤0.01% | 6503 |
|
|
2021
Q3 | $67K | Sell |
306
-2,333
| -88% | -$494K | ﹤0.01% | 5740 |
|
|
2021
Q2 | $612K | Buy |
2,639
+117
| +5% | +$29.8K | ﹤0.01% | 4573 |
|
|
2021
Q1 | $759K | Buy |
2,522
+494
| +24% | +$177K | ﹤0.01% | 4420 |
|
|
2020
Q4 | $763K | Buy |
2,028
+1,282
| +172% | +$449K | ﹤0.01% | 4118 |
|
|
2020
Q3 | $233K | Sell |
746
-192
| -20% | -$73.4K | ﹤0.01% | 4287 |
|
|
2020
Q2 | $353K | Buy |
938
+627
| +202% | +$178K | ﹤0.01% | 4007 |
|
|
2020
Q1 | $71K | Buy |
311
+200
| +180% | +$76.4K | ﹤0.01% | 4621 |
|
|
2019
Q4 | $59K | Hold |
111
| – | – | ﹤0.01% | 5067 |
|
|
2019
Q3 | $48K | Buy |
111
+18
| +19% | +$11.6K | ﹤0.01% | 5193 |
|
|
2019
Q2 | $107K | Buy |
93
+10
| +12% | +$12K | ﹤0.01% | 4908 |
|
|
2019
Q1 | $104K | Sell |
83
-233
| -74% | -$267K | ﹤0.01% | 4874 |
|
|
2018
Q4 | $298K | Buy |
316
+237
| +300% | +$285K | ﹤0.01% | 4397 |
|
|
2018
Q3 | $114K | Buy |
79
+11
| +16% | +$16.6K | ﹤0.01% | 4899 |
|
|
2018
Q2 | $110K | Buy |
+68
| New | +$117K | ﹤0.01% | 4807 |
|
|
2017
Q2 | – | Sell |
-77
| Closed | -$42K | – | 5051 |
|
|
2017
Q1 | $42K | Buy |
77
+46
| +148% | +$28.2K | ﹤0.01% | 4570 |
|
|
2016
Q4 | $19K | Buy |
+31
| New | +$19.3K | ﹤0.01% | 4708 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4774 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4725 |
|
|
2015
Q2 | – | Sell |
-755
| Closed | -$628K | – | 4080 |
|
|
2015
Q1 | $628K | Sell |
755
-251
| -25% | -$195K | ﹤0.01% | 3444 |
|
|
2014
Q4 | $724K | Buy |
+1,006
| New | +$787K | ﹤0.01% | 3511 |
|
Other funds holding CBIO
FFM
LGM
FIS
BCM
NCM
JP Morgan Chase's CBIO Position: Q2 2026 in Review
JP Morgan Chase reduced its Crescent Biopharma (CBIO) stake by 78% in Q2 2026, selling an estimated $624K and leaving 9,020 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #5732.
JP Morgan Chase first reported a position in CBIO in Q4 2014 and has held it in 33 quarters since. The position peaked at $763K in Q4 2020. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.
- JP Morgan Chase held 9,020 shares of Crescent Biopharma worth $162K as of Q2 2026.
- JP Morgan Chase sold 31,984 Crescent Biopharma shares in Q2 2026, an estimated $624K.
- Crescent Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5732 holding.
- JP Morgan Chase first reported a position in Crescent Biopharma in Q4 2014 and has held it in 33 quarters since.
- JP Morgan Chase's Crescent Biopharma position peaked at $763K in Q4 2020.
- 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.